Loading...

Fady Malik, MD, PhD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Phone415-353-3817
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San Francisco Clinical Fellowship School of Medicine
    University of California, San Francisco Residency School of Medicine
    University of California, San FranciscoM.D.1994 Medicine
    University of California, San FranciscoPh.D.1993 Graduate Division (Neuroscience)

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Collibee SE, Bergnes G, Muci A, Browne WF, Garard M, Hinken AC, Russell AJ, Suehiro I, Hartman J, Kawas R, Lu PP, Lee KH, Marquez D, Tomlinson M, Xu D, Kennedy A, Hwee D, Schaletzky J, Leung K, Malik FI, Morgans DJ, Morgan BP. Discovery of Tirasemtiv, the First Direct Fast Skeletal Muscle Troponin Activator. ACS Med Chem Lett. 2018 Apr 12; 9(4):354-358. PMID: 29670700.
      View in: PubMed
    2. Andrews JA, Cudkowicz ME, Hardiman O, Meng L, Bian A, Lee J, Wolff AA, Malik FI, Shefner JM. VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics. Amyotroph Lateral Scler Frontotemporal Degener. 2018 05; 19(3-4):259-266. PMID: 29402141.
      View in: PubMed
    3. O'Connor CM, Psotka MA, Fiuzat M, Lindenfeld J, Abraham WT, Bristow MR, Canos D, Harrington RA, Hillebrenner M, Jessup M, Malik FI, Solomon SD, Stockbridge N, Tcheng JE, Unger EF, Whellan DJ, Zuckerman B, Califf RM. Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory. J Am Coll Cardiol. 2018 Jan 30; 71(4):443-453. PMID: 29389362.
      View in: PubMed
    4. Andrews JA, Meng L, Kulke SF, Rudnicki SA, Wolff AA, Bozik ME, Malik FI, Shefner JM. Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis. JAMA Neurol. 2018 Jan 01; 75(1):58-64. PMID: 29181534.
      View in: PubMed
    5. Andrews JA, Miller TM, Vijayakumar V, Stoltz R, James JK, Meng L, Wolff AA, Malik FI. CK-2127107 amplifies skeletal muscle response to nerve activation in humans. Muscle Nerve. 2018 May; 57(5):729-734. PMID: 29150952.
      View in: PubMed
    6. Planelles-Herrero VJ, Hartman JJ, Robert-Paganin J, Malik FI, Houdusse A. Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil. Nat Commun. 2017 08 04; 8(1):190. PMID: 28775348.
      View in: PubMed
    7. Povsic TJ, Scott R, Mahaffey KW, Blaustein R, Edelberg JM, Lefkowitz MP, Solomon SD, Fox JC, Healy KE, Khakoo AY, Losordo DW, Malik FI, Monia BP, Montgomery RL, Riesmeyer J, Schwartz GG, Zelenkofske SL, Wu JC, Wasserman SM, Roe MT. Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference. Cardiovasc Drugs Ther. 2017 Aug; 31(4):445-458. PMID: 28735360.
      View in: PubMed
    8. Cowie MR, Filippatos GS, Alonso Garcia MLA, Anker SD, Baczynska A, Bloomfield DM, Borentain M, Bruins Slot K, Cronin M, Doevendans PA, El-Gazayerly A, Gimpelewicz C, Honarpour N, Janmohamed S, Janssen H, Kim AM, Lautsch D, Laws I, Lefkowitz M, Lopez-Sendon J, Lyon AR, Malik FI, McMurray JJV, Metra M, Figueroa Perez S, Pfeffer MA, Pocock SJ, Ponikowski P, Prasad K, Richard-Lordereau I, Roessig L, Rosano GMC, Sherman W, Stough WG, Swedberg K, Tyl B, Zannad F, Boulton C, De Graeff P. New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. Eur J Heart Fail. 2017 06; 19(6):718-727. PMID: 28345190.
      View in: PubMed
    9. Hwee DT, Cheng AJ, Hartman JJ, Hinken AC, Lee K, Durham N, Russell AJ, Malik FI, Westerblad H, Jasper JR. The Ca2+ sensitizer CK-2066260 increases myofibrillar Ca2+ sensitivity and submaximal force selectively in fast skeletal muscle. J Physiol. 2017 03 01; 595(5):1657-1670. PMID: 27869319.
      View in: PubMed
    10. Teerlink JR, Felker GM, McMurray JJ, Solomon SD, Adams KF, Cleland JG, Ezekowitz JA, Goudev A, Macdonald P, Metra M, Mitrovic V, Ponikowski P, Serpytis P, Spinar J, Tomcsányi J, Vandekerckhove HJ, Voors AA, Monsalvo ML, Johnston J, Malik FI, Honarpour N. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet. 2016 12 10; 388(10062):2895-2903. PMID: 27914656.
      View in: PubMed
    11. Sirigu S, Hartman JJ, Planelles-Herrero VJ, Ropars V, Clancy S, Wang X, Chuang G, Qian X, Lu PP, Barrett E, Rudolph K, Royer C, Morgan BP, Stura EA, Malik FI, Houdusse AM. Highly selective inhibition of myosin motors provides the basis of potential therapeutic application. Proc Natl Acad Sci U S A. 2016 11 22; 113(47):E7448-E7455. PMID: 27815532.
      View in: PubMed
    12. Wiklund I, Anatchkova M, Oko-Osi H, von Maltzahn R, Chau D, Malik FI, Patrick DL, Spertus J, Teerlink JR. Incorporating development of a patient-reported outcome instrument in a clinical drug development program: examples from a heart failure program. Health Qual Life Outcomes. 2016 Sep 15; 14(1):131. PMID: 27629389.
      View in: PubMed
    13. Psotka MA, von Maltzahn R, Anatchkova M, Agodoa I, Chau D, Malik FI, Patrick DL, Spertus JA, Wiklund I, Teerlink JR. Patient-Reported Outcomes in Chronic Heart Failure: Applicability for Regulatory Approval. JACC Heart Fail. 2016 10; 4(10):791-804. PMID: 27395351.
      View in: PubMed
    14. Manders E, Bonta PI, Kloek JJ, Symersky P, Bogaard HJ, Hooijman PE, Jasper JR, Malik FI, Stienen GJ, Vonk-Noordegraaf A, de Man FS, Ottenheijm CA. Reduced force of diaphragm muscle fibers in patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2016 07 01; 311(1):L20-8. PMID: 27190061.
      View in: PubMed
    15. Teerlink JR, Felker GM, McMurray JJV, Ponikowski P, Metra M, Filippatos GS, Ezekowitz JA, Dickstein K, Cleland JGF, Kim JB, Lei L, Knusel B, Wolff AA, Malik FI, Wasserman SM. Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. J Am Coll Cardiol. 2016 Mar 29; 67(12):1444-1455. PMID: 27012405.
      View in: PubMed
    16. Palaparthy R, Banfield C, Alvarez P, Yan L, Smith B, Johnson J, Monsalvo ML, Malik F. Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects. Int J Clin Pharmacol Ther. 2016 Mar; 54(3):217-27. PMID: 26709596; PMCID: PMC4776255.
      View in: PubMed, PubMed Central
    17. Teerlink JR, Malik FI, Kass DA. Letter by Teerlink et al Regarding Article, "Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity". Circ Heart Fail. 2015 Nov; 8(6):1141. PMID: 26578671; PMCID: PMC4654674 [Available on 11/01/16].
      View in: PubMed, PubMed Central
    18. Vu T, Ma P, Xiao JJ, Wang YM, Malik FI, Chow AT. Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure. J Clin Pharmacol. 2015 Nov; 55(11):1236-47. PMID: 25951506.
      View in: PubMed
    19. Sanders DB, Rosenfeld J, Dimachkie MM, Meng L, Malik FI. A Double-Blinded, Randomized, Placebo-Controlled Trial to Evaluate Efficacy, Safety, and Tolerability of Single Doses of Tirasemtiv in Patients with Acetylcholine Receptor-Binding Antibody-Positive Myasthenia Gravis. Neurotherapeutics. 2015 Apr; 12(2):455-60. PMID: 25742919; PMCID: PMC4404445.
      View in: PubMed, PubMed Central
    20. Hwee DT, Kennedy AR, Hartman JJ, Ryans J, Durham N, Malik FI, Jasper JR. The small-molecule fast skeletal troponin activator, CK-2127107, improves exercise tolerance in a rat model of heart failure. J Pharmacol Exp Ther. 2015 Apr; 353(1):159-68. PMID: 25678535.
      View in: PubMed
    21. Hansen R, Saikali KG, Chou W, Russell AJ, Chen MM, Vijayakumar V, Stoltz RR, Baudry S, Enoka RM, Morgans DJ, Wolff AA, Malik FI. Tirasemtiv amplifies skeletal muscle response to nerve activation in humans. Muscle Nerve. 2014 Dec; 50(6):925-31. PMID: 24634285; PMCID: PMC4260123.
      View in: PubMed, PubMed Central
    22. Greenberg BH, Chou W, Saikali KG, Escandón R, Lee JH, Chen MM, Treshkur T, Megreladze I, Wasserman SM, Eisenberg P, Malik FI, Wolff AA, Shaburishvili T. Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. JACC Heart Fail. 2015 Jan; 3(1):22-9. PMID: 25453536.
      View in: PubMed
    23. Bauer TA, Wolff AA, Hirsch AT, Meng LL, Rogers K, Malik FI, Hiatt WR. Effect of tirasemtiv, a selective activator of the fast skeletal muscle troponin complex, in patients with peripheral artery disease. Vasc Med. 2014 Aug; 19(4):297-306. PMID: 24872402.
      View in: PubMed
    24. Hwee DT, Kennedy A, Ryans J, Russell AJ, Jia Z, Hinken AC, Morgans DJ, Malik FI, Jasper JR. Fast skeletal muscle troponin activator tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model. PLoS One. 2014; 9(5):e96921. PMID: 24805850; PMCID: PMC4013064.
      View in: PubMed, PubMed Central
    25. Khodjaev SD, Teerlink JR, Malik FI. Novel drug mechanisms in development for heart failure. Pflugers Arch. 2014 Jun; 466(6):1219-25. PMID: 24793049.
      View in: PubMed
    26. Hooijman PE, Beishuizen A, de Waard MC, de Man FS, Vermeijden JW, Steenvoorde P, Bouwman RA, Lommen W, van Hees HW, Heunks LM, Dickhoff C, van der Peet DL, Girbes AR, Jasper JR, Malik FI, Stienen GJ, Hartemink KJ, Paul MA, Ottenheijm CA. Diaphragm fiber strength is reduced in critically ill patients and restored by a troponin activator. Am J Respir Crit Care Med. 2014 Apr 01; 189(7):863-5. PMID: 24684359; PMCID: PMC4225832.
      View in: PubMed, PubMed Central
    27. Miciak JJ, Warsing LC, Tibbs ME, Jasper JR, Jampel SB, Malik FI, Tankersley C, Wagner KR. Fast skeletal muscle troponin activator in the dy2J muscular dystrophy model. Muscle Nerve. 2013 Aug; 48(2):279-85. PMID: 23512724.
      View in: PubMed
    28. Ottenheijm CA, Buck D, de Winter JM, Ferrara C, Piroddi N, Tesi C, Jasper JR, Malik FI, Meng H, Stienen GJ, Beggs AH, Labeit S, Poggesi C, Lawlor MW, Granzier H. Deleting exon 55 from the nebulin gene induces severe muscle weakness in a mouse model for nemaline myopathy. Brain. 2013 Jun; 136(Pt 6):1718-31. PMID: 23715096; PMCID: PMC3673460.
      View in: PubMed, PubMed Central
    29. de Winter JM, Buck D, Hidalgo C, Jasper JR, Malik FI, Clarke NF, Stienen GJ, Lawlor MW, Beggs AH, Ottenheijm CA, Granzier H. Troponin activator augments muscle force in nemaline myopathy patients with nebulin mutations. J Med Genet. 2013 Jun; 50(6):383-92. PMID: 23572184; PMCID: PMC3865762.
      View in: PubMed, PubMed Central
    30. Lee EJ, De Winter JM, Buck D, Jasper JR, Malik FI, Labeit S, Ottenheijm CA, Granzier H. Fast skeletal muscle troponin activation increases force of mouse fast skeletal muscle and ameliorates weakness due to nebulin-deficiency. PLoS One. 2013; 8(2):e55861. PMID: 23437068; PMCID: PMC3577798.
      View in: PubMed, PubMed Central
    31. Shefner J, Cedarbaum JM, Cudkowicz ME, Maragakis N, Lee J, Jones D, Watson ML, Mahoney K, Chen M, Saikali K, Mao J, Russell AJ, Hansen RL, Malik F, Wolff AA. Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012 Sep; 13(5):430-8. PMID: 22591195.
      View in: PubMed
    32. Ho D, Chen L, Zhao X, Durham N, Pannirselvam M, Vatner DE, Morgans DJ, Malik FI, Vatner SF, Shen YT. Smooth muscle myosin inhibition: a novel therapeutic approach for pulmonary hypertension. PLoS One. 2012; 7(5):e36302. PMID: 22563487; PMCID: PMC3341368.
      View in: PubMed, PubMed Central
    33. Russell AJ, Hartman JJ, Hinken AC, Muci AR, Kawas R, Driscoll L, Godinez G, Lee KH, Marquez D, Browne WF, Chen MM, Clarke D, Collibee SE, Garard M, Hansen R, Jia Z, Lu PP, Rodriguez H, Saikali KG, Schaletzky J, Vijayakumar V, Albertus DL, Claflin DR, Morgans DJ, Morgan BP, Malik FI. Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. Nat Med. 2012 Feb 19; 18(3):452-5. PMID: 22344294; PMCID: PMC3296825.
      View in: PubMed, PubMed Central
    34. Cleland JG, Teerlink JR, Senior R, Nifontov EM, Mc Murray JJ, Lang CC, Tsyrlin VA, Greenberg BH, Mayet J, Francis DP, Shaburishvili T, Monaghan M, Saltzberg M, Neyses L, Wasserman SM, Lee JH, Saikali KG, Clarke CP, Goldman JH, Wolff AA, Malik FI. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet. 2011 Aug 20; 378(9792):676-83. PMID: 21856481.
      View in: PubMed
    35. Teerlink JR, Clarke CP, Saikali KG, Lee JH, Chen MM, Escandon RD, Elliott L, Bee R, Habibzadeh MR, Goldman JH, Schiller NB, Malik FI, Wolff AA. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet. 2011 Aug 20; 378(9792):667-75. PMID: 21856480.
      View in: PubMed
    36. Zhao X, Ho D, Abarzúa P, Dhar SK, Wang X, Jia Z, Pannirselvam M, Morgans DJ, Malik FI, Vatner SF. Inhibition of smooth muscle myosin as a novel therapeutic target for hypertension. J Pharmacol Exp Ther. 2011 Oct; 339(1):307-12. PMID: 21784887; PMCID: PMC3186291.
      View in: PubMed, PubMed Central
    37. Malik FI, Morgan BP. Cardiac myosin activation part 1: from concept to clinic. J Mol Cell Cardiol. 2011 Oct; 51(4):454-61. PMID: 21616079.
      View in: PubMed
    38. Malik FI, Hartman JJ, Elias KA, Morgan BP, Rodriguez H, Brejc K, Anderson RL, Sueoka SH, Lee KH, Finer JT, Sakowicz R, Baliga R, Cox DR, Garard M, Godinez G, Kawas R, Kraynack E, Lenzi D, Lu PP, Muci A, Niu C, Qian X, Pierce DW, Pokrovskii M, Suehiro I, Sylvester S, Tochimoto T, Valdez C, Wang W, Katori T, Kass DA, Shen YT, Vatner SF, Morgans DJ. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science. 2011 Mar 18; 331(6023):1439-43. PMID: 21415352; PMCID: PMC4090309.
      View in: PubMed, PubMed Central
    39. Morgan BP, Muci A, Lu PP, Qian X, Tochimoto T, Smith WW, Garard M, Kraynack E, Collibee S, Suehiro I, Tomasi A, Valdez SC, Wang W, Jiang H, Hartman J, Rodriguez HM, Kawas R, Sylvester S, Elias KA, Godinez G, Lee K, Anderson R, Sueoka S, Xu D, Wang Z, Djordjevic N, Malik FI, Morgans DJ. Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin. ACS Med Chem Lett. 2010 Dec 09; 1(9):472-7. PMID: 24900233; PMCID: PMC4007828.
      View in: PubMed, PubMed Central
    40. Shen YT, Malik FI, Zhao X, Depre C, Dhar SK, Abarzúa P, Morgans DJ, Vatner SF. Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure. Circ Heart Fail. 2010 Jul; 3(4):522-7. PMID: 20498236.
      View in: PubMed
    Fady's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (203) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (4) people
    _
    Similar People
    People who share similar concepts with this person.
    See all (59) people
    _
    Same Department
    Search Department
    ↑